Mesd is a chaperone protein necessary for the proper folding of the signal transduction receptors LRP5 and LRP6. Mesd-based peptides may be useful in the therapeutic regulation of LRP5 and LRP6.
“Mesd significantly adds to our growing franchise in the drug targeting area. Similar to our RAP molecule, Mesd is a natural human receptor chaperone protein that has the potential to act as both a receptor targeting therapeutic, as well as a targeted delivery platform that could be used to deliver other drugs,” said Dr Christopher Starr, CEO of Raptor.
Raptor Pharmaceuticals is an early stage biotechnology research and development company which bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins.